A clinical stage biopharmaceutical company developing best-in-class novel therapeutics to relieve the suffering of patients with neurodegenerative diseases, psychiatric disorders and pain.
Total raised: $17.5M
Investors 2
| Date | Name | Website |
| - | KTB Networ... | ktbnetwork... |
| - | WI Harper ... | wiharper.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.09.2017 | Series B | $17.5M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.09.2020 | XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer | - |
| 20.09.2017 | XW Labs Secures over $17M in Series B Financing | XW Laboratories Inc., a Wuhan, China-based biopharmaceutical Research and Development (R&D) company focused on neurological disorders, closed a $17.5m Series B financing. The round was led by Elements Capital and WI Harper with particip... |
| 20.09.2017 | China’s WuXi, Johnson & Johnson-backed XW Labs lands $17.5M series B | Chinese neurological disorders startup XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million. The funding boost was led by Elements Capital and WI Harper, with help from new invest... |